Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) develops and commercializes medicines for neurological, psychiatric, sleep, inflammatory and other conditions. Its commercial portfolio includes Fanapt for schizophrenia and acute manic or mixed episodes associated with bipolar I disorder; HETLIOZ for Non-24-Hour Sleep-Wake… From the company’s description.
Over the twelve months to Sep 30, 2026, Vanda Pharmaceuticals Inc. reported revenue of $229.28M, up 8.1% from a year earlier, and a net loss of $274.83M. Its operating margin was −77.6%, and operations used $139.14M in cash. In fiscal 2025, it reported revenue of $216.10M, up 8.7% from fiscal 2024, and a net loss of $220.47M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Vanda Pharmaceuticals Inc. does
In the company’s own words
Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) develops and commercializes medicines for neurological, psychiatric, sleep, inflammatory and other conditions. Its commercial portfolio includes Fanapt for schizophrenia and acute manic or mixed episodes associated with bipolar I disorder; HETLIOZ for Non-24-Hour Sleep-Wake Disorder and nighttime sleep disturbances in Smith-Magenis syndrome; PONVORY for relapsing forms of multiple sclerosis; and NEREUS for preventing motion-induced vomiting. Customers include patients and healthcare providers in the United States and, for some products, Canada, Europe and Israel. Vanda also develops product candidates and additional indications, including Bysanti for psychiatric disorders, imsidolimab for generalized pustular psoriasis, and candidates for gastrointestinal, dermatological, ophthalmic and genetic conditions. The company reports its business as a biopharmaceutical company, without segment breakdowns in the business description. In 2025, net sales were $117.3 million for Fanapt, $71.4 million for HETLIOZ and $27.4 million for PONVORY. Vanda was incorporated in 2002 and began operations in 2003. Its website is www.vandapharma.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- WASHINGTON, DC
- Fiscal year end
- December
- CIK
- 1347178
- SIC
- 2834
Financial performance, year by year
Fiscal 2011–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Vanda Pharmaceuticals Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Vanda Pharmaceuticals Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Vanda Pharmaceuticals Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Vanda Pharmaceuticals Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Vanda Pharmaceuticals Inc.'s last four quarterly filings that the numbers alone won't show?”